Newpath Partners is a multi-stage life sciences and healthcare venture capital firm based in Boston, MA. The firm partners with leading academic scientists at the earliest stages of company formation to translate scientific discoveries into transformative therapies.
71% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 4 prior). Their most common stage is series-b (41% of deals). Average disclosed round size is $101.1M (across 13 rounds with reported amounts).
Portfolio
14
Fund Size
$350M
Top Stage
Series B
Last 12 Mo
2
Team
BL
Ben L.
Investor
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
17 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Create Medicines | Series B | $122M | May 2026 |
| Create Medicines | Series B | $122M | Jan 2026 |
 Metsera | Series B | — | Nov 2024 |
 Leal Therapeutics | Series B | $45M | Oct 2024 |
 Autobahn Therapeutics | Series C | $100M | Jul 2024 |
 Autobahn | Series C | $100M | Jul 2024 |
| NnChroma | Unknown | $75M | Jan 2024 |
 Magnet Biomedicine | Series A | $50M | Sep 2023 |
 Myeloid Therapeutics | Series C | $73M | May 2023 |
 Orbital Therapeutics | Series A | $270M | Apr 2023 |
 Chroma Medicine | Series B | $135M | Mar 2023 |
| NNeumora Therapeutics, Inc. | Series A | — | Oct 2021 |
| KKojin Therapeutics | Series A | $60M | Jun 2021 |
| Myeloid Therapeutics | Unknown | $50M | Jan 2021 |
 Neumora Therapeutics | Series B | $112M | — |
| PPrime Medicine, Inc. | Series A | — | — |
| PPrime Medicine, Inc. | Series B | — | — |
Top Co-Investors
ARCH Venture Partners14 shared
Alexandria Venture Investments10 shared
F-Prime Capital5 shared
8VC4 shared
Casdin Capital4 shared
GV4 shared
Mubadala Ventures4 shared
Moore Strategic Ventures3 shared
Wellington Management3 shared
Cormorant Asset Management3 shared
T. Rowe Price3 shared
Primary Venture Partners2 shared
Atlas Venture2 shared
Omega Funds2 shared
Sofinnova Partners2 shared
Altitude Life Science Ventures2 shared
The Invus Group, LLC2 shared
Bristol Myers Squibb2 shared
Canaan Partners2 shared
Insight Partners2 shared
Last updated: 8 September 2026